Eli Lilly (LLY): what its SEC filings show
Two years of results through Q3 2026 (Jul–Sep 2026), in plain English. Every figure links to the SEC filing it came from.
Built by the Tribune's code from SEC filings. No AI wrote or changed any figure. No ratings or advice. Updated Nov. 3, 2026. Latest report: 10-Q, filed Oct. 29, 2026. Updates automatically when the company files its next report. How this page works
The latest quarter at a glance
Q3 2026 (Jul–Sep 2026) compared with Q3 2025.
What changed this quarter
Two-year trends
Revenue
All the money the company took in from sales, before any costs.
Net income
What was left after all costs, interest and taxes: the bottom line. Below the line is a loss.
Free cash flow
Cash brought in by running the business, minus spending on property and equipment. Below the line means the company spent more than it brought in that quarter.
Shares outstanding
How many shares exist. When the number rises, each share owns a smaller slice of the company.
Cash and short-term investments compared with debt
Cash on hand next to what the company owes in loans and bonds.
Warning-sign checks
Code looks for these filings in the last three years and reports only that a filing exists, never what it means for the stock.
Every figure and its filing
Each figure links to the 10-Q or 10-K it came from. "No data" means it wasn't filed in a form the methodology accepts; nothing is estimated.
| Figure | Q4 2024Oct–Dec 2024 | Q1 2025Jan–Mar 2025 | Q2 2025Apr–Jun 2025 | Q3 2025Jul–Sep 2025 | Q4 2025Oct–Dec 2025 | Q1 2026Jan–Mar 2026 | Q2 2026Apr–Jun 2026 | Q3 2026Jul–Sep 2026 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $13.5 billion | $12.7 billion | $15.6 billion | $17.6 billion | $19.3 billion | $19.8 billion | $23.0 billion | $24.4 billion |
| Net income | $4.4 billion | $2.8 billion | $5.7 billion | $5.6 billion | $6.6 billion | $7.4 billion | $7.1 billion | $6.5 billion |
| Cash from operations | $2.5 billion | $1.7 billion | $3.1 billion | $8.8 billion | $3.2 billion | $5.3 billion | $10.7 billion | $11.4 billion |
| Spending on property and equipment | No data | No data | No data | No data | No data | No data | No data | No data |
| Free cash flow (calculated) | No data | No data | No data | No data | No data | No data | No data | No data |
| Gross margin (calculated) | No data | No data | No data | No data | No data | No data | No data | No data |
| Shares outstanding | 948 million | 948 million | 946 million | 945 million | 943 million | 942 million | 941 million | 941 million |
| Cash and short-term investments (calculated) | $3.4 billion | $3.2 billion | $3.5 billion | $9.9 billion | No data | No data | No data | No data |
| Debt (calculated) | $33.6 billion | $38.5 billion | $39.9 billion | $42.5 billion | $42.5 billion | $43.4 billion | $54.9 billion | $49.5 billion |
Want an alert when Eli Lilly files something important?
Alerts aren't available yet. Tap the button if you'd use them. It only adds one to a count: no email, no sign-up.
Thanks, your interest in Eli Lilly alerts is counted. If enough readers want alerts, we'll build them. Meanwhile, this page updates automatically each time Eli Lilly files a new report, so check back after its next earnings.
Figures as filed in 10-Q and 10-K reports; the latest filing wins. Single quarters, the fourth quarter (the full year minus the first nine months), free cash flow, margins and changes are calculated by the Tribune. Methodology version 1.2. How this page works · All of Eli Lilly's filings on SEC EDGAR